Trxade, Inc (MEDS) Corporate Media Kit

14 NASDAQ: MEDS • • Rapid Growth: 94% YoY growth in FY2019 with strong sequential growth • High Margin: Revenue from transaction fees (Credit Card/PayPal model) does not include the drugs value (over $100M annually), hence “tech like margins” • Built-Out Platform: Continued platform development is always ongoing, but requires minimal capital investment on a go-forward basis • Positive Adj. EBITDA: $500K in adjusted EBITDA in Q2 2020* • Strong Balance Sheet : $4.2 million in cash with limited debt provides strong foundation for growth Selected Financials (USD $ in Millions) TTM June 30, 2020 TTM June 30, 2019 Revenue $12.8 $5.6 Gross Profit $6.2 $4.0 Operating Income $(0.2) $0.1 Net Income (Loss) $(0.8) $0.1 (USD $ in Millions) June 30, 2020 June 30, 2019 Cash & Cash Equivalents $4.2 $0.5 Debt $0.2 $0.5 Annual Revenue Growth (USD $ in Thousands) $806 $956 $1,496 $4,992 $2,482 $2,931 $3,832 $7,436 2012 2013 2014 2015 2016 2017 2018 2019 *Adj. EBITDA (Loss) is a non-GAAP term, net income before interest, taxes, depreciation and amortization as well as share in equity loss on investment and stock based compensation. See appendix for a reconciliation of these amounts to GAAP.